Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Fig. 3

HDACi increase decitabine-induced CTA expression in Meso96 cells and allow tumor cell recognition by CD8+ NY-ESO-1 T-cell clone. Meso96 cells were treated with: VPA 5 mM, SAHA 2.5 μM, ODB 7.5 μM, NODB 2.5 μM, ODH 2.5 μM, and NODH 25 nM (48 h) in combination or not with decitabine (5-aza) 500 nM (72 h pretreatment). NY-ESO-1 (a), MAGE-A1 (c), MAGE-A3 (d), XAGE-1b (e), and PD-L1 (f) mRNA were measured using real time PCR. *p < 0.05, **p < 0.01 and ***p < 0.001. b Interferon (IFN-γ) production by NY-ESO-1-specific CD8+ T-cell clone in response to Meso96 treated or not with the combination decitabine +/− HDACi. IFN-γ production was measured by intracytoplasmic staining of IFN-γ and surface staining of CD8, followed by flow cytometry analysis. Lc: lymphocytes alone, +: NY-ESO-1 (157–165) peptide (10 μM), −: MUC1 (950–958) peptide (10 μM), M117: melanoma cell line that expresses NY-ESO-1, CT: untreated Meso96 cells. Results are expressed as the means ± S.E.M of three independent experiments. § vs LC, §§p < 0.001, §§§p < 0.001; * vs CT, *p < 0.05 and **p < 0.01

Back to article page